SARS-CoV-2 and HCoV-OC43 belong to the same beta genus of the Coronaviridae family. SARS-CoV-2 was responsible for the recent COVID-19 pandemic, and HCoV-OC43 is the etiological agent of mild upper respiratory tract infections. SARS-COV-2 and HCoV-OC43 co-infections were found in children with respiratory symptoms during the COVID-19 pandemic. The two beta-coronaviruses share a high degree of homology between the 3CLpro active sites, so much so that the safer HCoV-OC43 has been suggested as a tool for the identification of new anti-SARS-COV-2 agents. Compounds 5 and 24 inhibited effectively both Wuhan and British SARS-CoV-2 patient isolates in Vero E6 cells and the HCoV-OC43 in MRC-5 cells at low micromolar concentrations. The inhibition was apparently exerted via targeting the 3CLpro active sites of both viruses. Compounds 5 and 24 at 100 mu M inhibited the SARS-CoV-2 3CLpro activity of 61.78 and 67.30%, respectively. These findings highlight 5 and 24 as lead compounds of a novel class of antiviral agents with the potential to treat SARS-COV-2 and HCoV-OC43 infections.

4-(3-Phenylsulfonylindol-2-yl)-1-(pyridin-2-yl)piperazinyl-methanones as Potent Inhibitors of both SARS-CoV-2 and HCoV-OC43 Viruses

Puxeddu, Michela
Co-first
;
Donalisio, Manuela
Co-first
;
Arduino, Irene;Coluccia, Antonio;Lembo, David;Silvestri, Romano;
2024-01-01

Abstract

SARS-CoV-2 and HCoV-OC43 belong to the same beta genus of the Coronaviridae family. SARS-CoV-2 was responsible for the recent COVID-19 pandemic, and HCoV-OC43 is the etiological agent of mild upper respiratory tract infections. SARS-COV-2 and HCoV-OC43 co-infections were found in children with respiratory symptoms during the COVID-19 pandemic. The two beta-coronaviruses share a high degree of homology between the 3CLpro active sites, so much so that the safer HCoV-OC43 has been suggested as a tool for the identification of new anti-SARS-COV-2 agents. Compounds 5 and 24 inhibited effectively both Wuhan and British SARS-CoV-2 patient isolates in Vero E6 cells and the HCoV-OC43 in MRC-5 cells at low micromolar concentrations. The inhibition was apparently exerted via targeting the 3CLpro active sites of both viruses. Compounds 5 and 24 at 100 mu M inhibited the SARS-CoV-2 3CLpro activity of 61.78 and 67.30%, respectively. These findings highlight 5 and 24 as lead compounds of a novel class of antiviral agents with the potential to treat SARS-COV-2 and HCoV-OC43 infections.
2024
10
9
3158
3175
https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00108
3CL protease; HCoV-OC43; SARS-CoV-2; antiviral drugs; synthesis
Puxeddu, Michela; Donalisio, Manuela; Bugert, Joachim Jakob; Corona, Angela; Cocomazzi, Paolo; Milani, Mario; Hucke, Friederike; Arduino, Irene; Espos...espandi
File in questo prodotto:
File Dimensione Formato  
puxeddu-et-al-2024-4-(3-phenylsulfonylindol-2-yl)-1-(pyridin-2-yl)piperazinyl-methanones-as-potent-inhibitors-of-both (2).pdf

Accesso aperto con embargo fino al 03/08/2025

Descrizione: pdf editoriale
Tipo di file: PDF EDITORIALE
Dimensione 6.77 MB
Formato Adobe PDF
6.77 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/2013530
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact